Five things for pharma marketers to know: Tuesday, June 7, 2016

1. Gilead Sciences CEO John Milligan talks drug pricing, telling The Wall Street Journal that “the lesson is we have to do a lot better job talking about the value we provide.” He also discussed the company's growth strategy as its HIV portfolio ages and competition has challenged Harvoni and Sovaldi, its blockbuster hepatitis-C duo. (WSJ)

2. Drugmakers that market multiple-sclerosis drugs are studying the overall cost of care and found that certain, expensive MS drugs may drive down other healthcare costs like outpatient services and hospitalizations. (MedPage Today)

3. At the ASCO meeting in Chicago, Vice President Joe Biden announced the launch of a national cancer database. Doctors, researchers, and life science companies can share data, which will also include all information from trials funded by the National Cancer Institute. (Fortune)

4. Genentech and OSI Pharmaceuticals will pay $67 million to settle allegations that they made misleading statements about the effectiveness of their cancer drug Tarceva. (WaPo)

5. Pfizer's experimental opioid drug, Troxyca ER, can be manipulated for abuse, according to FDA staff. The agency found that oxycodone can still be extracted using certain solvents. (Reuters)